CorMedix Inc Aktie News

PARSIPPANY, N.J., 1. Sept. 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Kommerzialisierung therapeutischer Produkte für lebensbedrohliche Krankheiten und Zustände konzentriert, gab heute bekannt, dass die Unternehmensführung an einem Fireside-Chat und Investorengesprächen auf der bevorstehenden 21. Wells Far...

‒ Konsolidierter Umsatz für Q2 2026 in Höhe von 101,9 Mio. USD ‒ ‒ Nettogewinn für Q2 2026 in Höhe von 26,0 Mio. USD; bereinigtes EBITDA von 58,7 Mio. USD ‒ ‒ Unternehmen bestätigt Umsatzprognose für FY 2026 und hebt bereinigtes EBITDA-Ausblick an ‒ ‒ Konferenzgespräch heute um 8:30 Uhr Eastern Time geplant ‒ PARSIPPANY, N.J.

PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that the patents covering its product MINOCIN® for Injection are valid and infringed by the product developed by Nexus Pharmaceuticals, Inc.

PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets Global Healthcare Conference being held in New York on May 19 – 20, 2026 and the Jefferies Global Healthcare Conference being held in New York on June 2 – 4, 2026. Details for each fi...

‒ Q1 2026 Net Revenue of  $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 14, 2026, and will host a corporate update conference call at 8:30am Eastern Time.

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –